Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Stage

Acquired Unit | Acquired

About NovImmune - emapalumab Unit

NovImmune is a biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

NovImmune - emapalumab Unit Headquarter Location

14 Chemin des Aulx Plan-Les-Ouates

Geneva, CH-1228,

Switzerland

+41 22 839 71 41

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NovImmune - emapalumab Unit

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NovImmune - emapalumab Unit is included in 1 Expert Collection, including Cancer.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.